Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00432601 |
The purpose of this study is to test different methods for communicating information about prostate cancer treatment to men. We are studying how best to present information so men can make good decisions about what prostate cancer treatment to undergo.
Condition | Intervention |
---|---|
Prostate Cancer |
Behavioral: type of decision aid |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study |
Official Title: | Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making |
Estimated Enrollment: | 500 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | July 2010 |
Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Patients will receive Michigan Cancer Consortium decision aid.
|
Behavioral: type of decision aid
We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
|
2: Active Comparator
Patients will receive National Comprehensive Cancer Network decision aid.
|
Behavioral: type of decision aid
We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
|
Background:
Background/Rationale: Prostate cancer is the second leading cause of related death among men in the United States, and accounts for 33% of all cancers diagnosed in men. Furthermore, approximately one in six men will be diagnosed with prostate cancer in their lifetime. Thus, 17% of male Veterans will be asked to make a decision about the treatment of their prostate cancer. The burden of this disease is further magnified when one considers that most patients, once diagnosed, will live for years following their diagnosis and with any adverse effects of therapy. Given that there have been no clinical trails which have proven that any prostate cancer treatment produces an increased likelihood of survival; men are asked to actively participate in decisions about what treatment to undergo. Previous research has revealed that men are often uninformed about their prostate cancer, particularly African American men and men with lower educational attainment. Thus, it is critical to develop and test decision aids that can help all men (especially men with low literacy skills) make an informed decision. However, this study will go beyond most decision aid research which has focused primarily on knowledge, treatment choice, and decisional conflict and will examine the impact of a decision aid on patient-physician interactions. Furthermore, invirtually no research has tested the use of decision aids with low literacy patients, as this study will.
Objectives:
Objective(s): To test the impact of a plain language decision aid (i.e., a low reading level) on prostate cancer patient's decision making experience and in their interactions with their physician and the VA health system. This study will also test if there are differences in receipt of active treatment between men with low vs. high literacy skills.
Methods:
Methods: The proposed study will be a randomized controlled trial. Men who are undergoing a prostate biopsy to will be recruited at the time of biopsy and those patients with a positive biopsy result will be interviewed at 3 time points: Baseline (at pre-biopsy appointment), at physician visit (diagnosis), and 10 days following physician visit (phone survey). Also, the treatment discussion between patients and their physician will be taped and coded.
Major characteristics: All men, without a prior history of prostate cancer, undergoing a prostate biopsy will be screened for eligibility and enrolled by the study coordinator before they undergo a prostate biopsy. Additional inclusion criteria include ability to speak English, provide informed consent, and having a 5 year or greater expected survival as determined by their physician. Physicians can refuse to allow a patient participate in the study at the time of biopsy. 500 men will be recruited at 4 VAs: Ann Arbor, Pittsburgh, San Francisco and Durham. Men will be randomized to either receive one of two types of decision aids.
Major variables and source(s) of data: All survey data will come from either face-to-face or phone interviews. Survey variables testing the impact of the decision aid will include: 1) treatment decision, 2) involvement in the decision making process, 3) knowledge of risks and benefits, 4) self-efficacy for decision making, and 5) satisfaction with decision aid.
Status:
Recruitment began 9/2/08.
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Must be undergoing a prostate cancer biopsy at Ann Arbor, Durham, San Francisco, or Pittsburgh VAs
Exclusion Criteria:
Prior history of prostate cancer
Contact: Julie Parow, BA | (734) 936-4175 | jparow@Umich.edu |
United States, California | |
VA Medical Center | Not yet recruiting |
San Francisco, California, United States, 94121 | |
Contact: Julie Parow, BA 734-936-4175 jparow@Umich.edu | |
Sub-Investigator: Sara J. Knight, PhD | |
Sub-Investigator: Christopher Kane, MD | |
United States, Michigan | |
VA Ann Arbor Healthcare System | Recruiting |
Ann Arbor, Michigan, United States, 48113-0170 | |
Contact: Angela Fagerlin, PhD MA fagerlin@umich.edu | |
Contact: Janet G Adams-Watson, MHSA BA (734) 845-3604 jan.adams-watson@va.gov | |
Principal Investigator: Angela Fagerlin, PhD MA | |
Sub-Investigator: Peter A. Ubel, MD | |
Sub-Investigator: Khaled Hafez, MBBS | |
United States, North Carolina | |
VA Medical Center, Durham | Not yet recruiting |
Durham, North Carolina, United States, 27705 | |
Contact: Julie Parow, BA 734-936-4175 jparow@Umich.edu | |
Sub-Investigator: Stewart C. Alexander, BA MA PhD | |
Sub-Investigator: James A. Tulsky, MD | |
United States, Pennsylvania | |
Center for Health Equity Research and Promotion | Not yet recruiting |
Pittsburgh, Pennsylvania, United States, 15206 | |
Contact: Julie Parow, BA 734-936-4175 jparow@Umich.edu | |
Sub-Investigator: Bruce S. Ling, MD MPH |
Principal Investigator: | Angela Fagerlin, PhD MA | VA Ann Arbor Healthcare System |
Responsible Party: | Department of Veterans Affairs ( Fagerlin, Angela - Principal Investigator ) |
Study ID Numbers: | IIR 05-283 |
Study First Received: | February 6, 2007 |
Last Updated: | February 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00432601 History of Changes |
Health Authority: | United States: Federal Government |
decision aid prostate cancer patient-physician communication decision making literacy |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |